This article has been cited by
1Enhanced Anti-Inflammatory Effects of Nanoencapsulated Diclofenac
J.Z. Goh,S.N. Tang,A. Zuraini,Z.A. Zakaria,A.A. Kadir,H.S. Chiong,M.S.O. Fauzee,M.N. Hakim
European Journal of Inflammation.2013;11(3)855
[DOI]
2An Open-Label, 52-Week, Phase III Trial of Duloxetine in Japanese Patients with Chronic Low Back Pain
Shin-ichi Konno,Levent Alev,Natsuko Oda,Toshimitsu Ochiai,Hiroyuki Enomoto
Pain Medicine.2019;20(8)1479
[DOI]
3Causes and consequences of the opioid epidemic in the Netherlands: a population-based cohort study
Ajda Bedene,Eveline L. A. van Dorp,Tariq Faquih,Suzanna C. Cannegieter,Dennis O. Mook-Kanamori,Marieke Niesters,Monique van Velzen,Maaike G. J. Gademan,Frits R. Rosendaal,Marcel L. Bouvy,Albert Dahan,Willem M. Lijfering
Scientific Reports.2020;10(1)1479
[DOI]
4Randomized, Double-blind, Placebo-controlled Phase III Trial of Duloxetine Monotherapy in Japanese Patients With Chronic Low Back Pain
Shinichi Konno,Natsuko Oda,Toshimitsu Ochiai,Levent Alev
Spine.2016;41(22)1709
[DOI]
  Feedback 
  Subscribe